Cytiva and WhiteLab Genomics Partner to Accelerate AI-Driven Stable Cell Line Development for AAV
Collaboration leverages AI-driven predictive modeling to cut AAV stable cell line development timelines by up to 70%, reducing cost and accelerating path to clinic.
Stable cell line development has long been a bottleneck in AAV-based genomic medicine manufacturing. A new collaboration between Cytiva and WhiteLab Genomics aims to change that, using artificial intelligence to cut development timelines and costs by as much as 70%.
WhiteLab Genomics will apply its proprietary AI-driven predictive modeling platform to improve stable cell line clone selection through in silico simulations, enabling faster and more reliable outcomes. Coupled with Cytiva’s established expertise in AAV production platforms, the collaboration is designed to help drug developers move candidates into the clinic and toward commercialization more efficiently.
“Through the integration of AI-driven predictive modeling into AAV development workflows, we aim to reduce development timelines and associated costs by up to 70%,” said David Del Bourgo, CEO and Co-Founder of WhiteLab Genomics. “That efficiency is critical as the industry pushes toward more scalable, commercially viable genomic therapies.”
According to Cytiva, the approach will not only save time and cost but also help manufacturers meet regulatory expectations around consistency and scalability.
“Genomic medicines will be critical to address some of the world’s greatest health challenges,” said Emmanuel Abate, President of Genomic Medicine at Cytiva. “By combining Cytiva’s experience with WhiteLab’s technology, we intend to help manufacturers reach clinical and regulatory milestones faster, ultimately benefiting patients worldwide.”
With mounting pressure across the industry to shorten time to IND and accelerate commercialization, the partnership highlights the increasing role of AI in optimizing advanced therapy workflows.
Author
BioFocus Newsroom